Arvinas Inc. released a corporate presentation outlining updates on its PROTAC protein degrader pipeline in oncology and neurology. The company highlighted vepdegestrant (ARV-471), an oral estrogen receptor degrader for metastatic breast cancer, noting a submitted U.S. FDA new drug application with a PDUFA date of June 5, 2026, and ongoing combination trials. The presentation also covered luxdegalutamide (ARV-766/JSB462), an androgen receptor degrader licensed to Novartis and being evaluated in Phase 2 combination trials in metastatic prostate cancer settings, and provided pipeline updates including ARV-102 (LRRK2) in Phase 1 for Parkinson’s disease, ARV-027 for spinal bulbar muscular atrophy, ARV-806 (KRAS G12D) in Phase 1 solid tumors, ARV-393 (BCL6) in Phase 1 for non-Hodgkin lymphoma, and ARV-6723 (HPK1) in preclinical development for advanced solid tumors. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.